TAA/CD4OL composition/vaccine for malaria
US10183067B1 · kind B1 · utility
Assignee
Inventor
Key dates
| Filing date | May 5, 2017 |
| Grant date | Jan 22, 2019 |
| Priority date | — |
| Expiry date | May 5, 2037 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are compositions and methods of selecting at least three fragments one each from three domains of the malarial CSP for generating antigen specific CD8 effector T cells and non-cross reacting neutralizing antibody immune responses to the malarial parasite, which when administered prevent an infection of a human being when bitten by a malaria infected mosquito. The composition and method comprises priming an individual by administering a mixture of one or more adenoviral expression vectors encoding one or more fusion proteins, which comprises the malarial CSP antigen fragments linked to the extracellular domain of the CD40 ligand. The adenoviral expression vector comprises a transcription unit encoding a secretable fusion protein, the fusion protein containing selected malarial sporozoite CSP antigen fragments linked to the CD40 ligand to block the attachment to or infection of the human liver cell(s) by the malarial sporozoite.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.